B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis
DelveInsight's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 75 major companies are actively engaged in the development of more than 80 treatment therapies for B-cell non-Hodgkin lymphoma.
B-cell Non-hodgkin Lymphoma Overview:
B-cell non-Hodgkin lymphoma (NHL) is a type of cancer that arises from abnormal B lymphocytes—white blood cells essential to the immune system. It accounts for over 85% of all NHL cases, making it the most common subtype. B-cell NHL includes several subtypes, classified based on cell morphology, surface proteins, and genetic traits. Key subtypes include diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Burkitt lymphoma. The disease typically starts in the lymph nodes or lymphoid tissues and can spread to other organs, such as the gastrointestinal tract. Common symptoms include painless swollen lymph nodes, fever, night sweats, fatigue, weight loss, itchy skin, and pain in the chest, abdomen, or bones. When fever, night sweats, and weight loss occur together, they are known as B symptoms and are important for staging and prognosis.
Diagnosing B-cell NHL—especially types with small- to medium-sized cells—can be difficult due to their resemblance to reactive lymphadenopathy and other lymphomas. Accurate diagnosis relies on a combination of techniques, including immunohistochemistry and flow cytometry, which must be interpreted in the context of the patient's clinical presentation and cellular morphology. Proper recognition of cytologic features is key to choosing the right diagnostic tests. Subtypes such as marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, CLL/SLL, and lymphoplasmacytic lymphoma are often misdiagnosed based on cytology alone. Therefore, a lymph node biopsy is usually necessary for definitive diagnosis and proper classification.
"B-cell Non-hodgkin Lymphoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-cell Non-hodgkin Lymphoma Therapeutics Market.
Key Takeaways from the B-cell Non-hodgkin Lymphoma Pipeline Report
DelveInsight's B-cell Non-hodgkin Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for B-cell Non-hodgkin Lymphoma treatment.
In May 2023, Bristol Myers Squibb announced positive topline results from two studies: TRANSCEND FL, a global, multicenter Phase 2 study evaluating Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1 study assessing Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met the primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.
In May 2023, Janssen Biotech, a subsidiary of Johnson & Johnson, announced a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation CAR T-cell therapies for treating B-cell malignancies.
In May 2023, Genmab A/S revealed that the FDA approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, after two or more lines of systemic therapy.
In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech to continue their collaboration and option agreement under revised terms, leading to the termination of the agreement and the winding down of all collaboration activities in the first quarter of 2023.
Key B-cell Non-hodgkin Lymphoma companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy, Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others are evaluating new drugs for B-cell Non-hodgkin Lymphoma to improve the treatment landscape.
Promising B-cell Non-hodgkin Lymphoma pipeline therapies in various stages of development include Valemetostat, MB-106, CB-010, LP-284, and others.
B-cell Non-hodgkin Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the B-cell Non-hodgkin Lymphoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Non-hodgkin Lymphoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-cell Non-hodgkin Lymphoma market.
Download our free sample page report on B-cell Non-hodgkin Lymphoma pipeline insights
B-cell Non-hodgkin Lymphoma Emerging Drugs
Valemetostat: Daiichi Sankyo
MB-106: Mustang Bio
CB-010: Caribou Biosciences
LP-284: Lantern Pharma
B-cell Non-hodgkin Lymphoma Companies
Over 75 key companies are working on developing therapies for B-cell non-Hodgkin lymphoma. Among them, Daiichi Sankyo has drug candidates for B-cell non-Hodgkin lymphoma in the advanced Phase II stage.
DelveInsight's report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
B-cell Non-hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
B-cell Non-hodgkin Lymphoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging B-cell Non-hodgkin Lymphoma Therapies and Key Companies: B-cell Non-hodgkin Lymphoma Clinical Trials and advancements
B-cell Non-hodgkin Lymphoma Pipeline Therapeutic Assessment
• B-cell Non-hodgkin Lymphoma Assessment by Product Type
• B-cell Non-hodgkin Lymphoma By Stage
• B-cell Non-hodgkin Lymphoma Assessment by Route of Administration
• B-cell Non-hodgkin Lymphoma Assessment by Molecule Type
Download B-cell Non-hodgkin Lymphoma Sample report to know in detail about the B-cell Non-hodgkin Lymphoma treatment market @ B-cell Non-hodgkin Lymphoma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. B-cell Non-hodgkin Lymphoma Current Treatment Patterns
4. B-cell Non-hodgkin Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. B-cell Non-hodgkin Lymphoma Late-Stage Products (Phase-III)
7. B-cell Non-hodgkin Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. B-cell Non-hodgkin Lymphoma Discontinued Products
13. B-cell Non-hodgkin Lymphoma Product Profiles
14. B-cell Non-hodgkin Lymphoma Key Companies
15. B-cell Non-hodgkin Lymphoma Key Products
16. Dormant and Discontinued Products
17. B-cell Non-hodgkin Lymphoma Unmet Needs
18. B-cell Non-hodgkin Lymphoma Future Perspectives
19. B-cell Non-hodgkin Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the B-cell Non-hodgkin Lymphoma Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
There is no safe amount of processed meat to eat, according to new research
The equivalent of one medium-size hot dog was associated with an increased risk of colorectal cancer and Type 2 diabetes in a new study. (RiverRockPhotos/iStockphoto/Getty Images via CNN Newsource) There is strong evidence that there is 'no safe amount' of processed meat to eat, nutrition experts say in response to a new study on the connection between diet and the risk of major diseases, including cancer, Type 2 diabetes and heart disease. The researchers also found elevated risks from the consumption of sugar-sweetened beverages and trans fatty acids. Researchers analyzed data from more than 60 previous studies on the relationship between processed meats, sugar-sweetened beverages and trans fatty acids in a person's diet and their risk of Type 2 diabetes, colorectal cancer and ischemic heart disease, which reduces blood supply to the heart and cuts off oxygen and nutrients, according to the study published Monday in the journal Nature Medicine. 'Habitual consumption of even small amounts of processed meat, sugary drinks, and trans fatty acids is linked to increased risk of developing Type 2 diabetes, ischemic heart disease and colorectal cancer,' said lead author of the study, Dr. Demewoz Haile, a research scientist at the Institute for Health Metrics and Evaluation in Seattle. The data showed that people who ate as little as one hot dog a day when it comes to processed meats had an 11% greater risk of Type 2 diabetes and a 7% increased risk of colorectal cancer than those who didn't eat any. And drinking the equivalent of about a 12-ounce soda per day was associated with an 8% increase in Type 2 diabetes risk and a 2% increased risk of ischemic heart disease. 'This current research has shown, yet again and consistent with prior research … that to achieve health gains it is best to avoid or minimize the habitual consumption of each of processed meat, sugar-sweetened beverages (SSBs) and industrially produced trans fatty acids (TFAs),' said Dr. Nita Forouhi, head of nutritional epidemiology at the University of Cambridge in the United Kingdom. She was not involved in the research. The risk increased as consumption increased; and for processed meat consumption, the data showed that there is no 'safe amount,' she added in an email. A stronger association than it may appear At first glance, the increase in risk seems modest and might look like the association is weak, said Dr. Mingyang Song, associate professor of clinical epidemiology and nutrition at the Harvard T.H. Chan School of Public Health. He was not involved in the research. 'When we look at the actual data there, it's really remarkably consistent and remarkably strong, and even in the lower dose of consumption, we can still see an increased risk of disease,' he said. The researchers examined dozens of earlier findings on diet and disease using a burden-of-proof method: a newer form of meta-analysis that not only tries to quantify an association across multiple studies but also accounts for the quality of each, Song said. 'One caveat is it tends to give very conservative results,' he added. It's also important to note that the studies included in the analysis were observational, meaning that the data can only show an association between eating habits and disease –– not prove that what people ate caused the disease. They also relied on people recalling their dietary patterns, which can leave room for misremembering or misreporting, said Dr. Gunter Kuhnle, professor of nutrition and food science at the University of Reading in the United Kingdom. He was not involved in the study. Utilizing even 'the most sophisticated techniques does not really solve the problem that the information about diet is rather limited – which is obviously a big problem in nutritional epidemiology in general,' he said. Why meats, drinks and fats are linked to disease There are many reasons why such foods could be associated with health problems. Sugar-sweetened beverages and processed meat –– such as sausages, bacon, salami and burgers –– can increase inflammation, which plays a big part in a variety of chronic diseases, Song said. Processed meats are also often cured with nitrite, which is converted to carcinogenic nitrosamines in the stomach, Kuhnle said. The problem with sugary drinks is that they are a quick way to consume large amounts of sugar, he added. Not only can that cause weight gain, but it also influences metabolic pathways that affect heart disease and diabetes risk, Kuhnle said. Trans fatty acids reduce levels of good cholesterol and increase the bad, which is known to increase the risk of plaque buildup in arteries and heart disease, he added. Other potential connections to consider are that people who are more likely to eat processed meats, sugar-sweetened beverages and trans-fats are often also at a higher risk of diseases because of 'lifestyle factors (smoking, lack of exercise), but also social factors such as education and income, chronic stress and limited access to health care,' Kuhnle said. 'It is very difficult to take these apart.' What to avoid and what to add Although the data can't say reducing your consumption of these foods and drinks will cause a lower risk of the diseases, it does suggest that a reduction is a good idea, Song said. A sensible approach is to follow a varied and balanced diet that avoids excess, Kuhnle said. That means people who drink a lot of sugary drinks should cut back, he said. It can also be helpful to avoid excess amounts of processed meats and avoid hydrogenated fats where possible –– although they are no longer as common as they used to be, he said. 'The goal shouldn't be perfection but rather a healthy and sensible dietary pattern that allows room for enjoyment,' Kuhnle said. A good diet isn't just about what to avoid. It's also important to get good nutrients, Forouhi said. 'Wider research has shown us that overall dietary patterns that include higher consumption of fruit and vegetables, whole grains, legumes, nuts and fermented dairy products like yogurt are good for health and longevity,' she said. 'My general advice: don't panic,' Kuhnle said in an email. 'Food is not just (a) source of nutrients –– it plays a central role in culture, pleasure, family life, and social connection. Reducing it solely to a list of health risks misses the bigger picture.' By Madeline Holcombe, CNN
Globe and Mail
2 hours ago
- Globe and Mail
Why Did Oscar Health Crash on Wednesday and Is This a Huge Buying Opportunity?
In this video, I explain why Oscar Health (NYSE: OSCR) crashed 18% on Wednesday and why I will buy shares. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock prices used were from the trading day of July 2, 2025. The video was published on July 2, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Should you invest $1,000 in Oscar Health right now? Before you buy stock in Oscar Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Oscar Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $697,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $939,655!* Now, it's worth noting Stock Advisor 's total average return is1,045% — a market-crushing outperformance compared to178%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Neil Rozenbaum has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Neil is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Globe and Mail
4 hours ago
- Globe and Mail
‘Carney may have caved, but the rest of us don't have to.' Letters to the editor for July 3
Re 'Like Terry Fox, RBC executive refused to be defeated by bone cancer' (Report on Business, July 1): Bravo to The Globe for the achingly beautiful story about the inspirational Chinyere Eni. Now, more than ever, Canadians need to celebrate our heroes. Chinyere is a master class in courage, grit, passion and determination. Like Terry Fox, she represents the best of the Canadian values our country was built upon. I first met Chinyere at the first Ride to Conquer Cancer event in 2008. Her daunting push to the finish line of the 100-kilometre hilly course brought thousands of riders to their feet and many of us to tears. Her story became embedded in the DNA of the ride, now in its 18th year of raising funds for cancer research at the Princess Margaret Cancer Centre. I hope we all get a chance to reflect on our Canadian heroes like Terry Fox and Chinyere Eni. Parents and grandparents, may I suggest you take a few minutes to share Chinyere's story with your kids this week. It is a made-in-Canada story about a transformational Canadian hero very much worth sharing. Paul Alofs, former CEO of the Princess Margaret Cancer Foundation Toronto Re 'Newfoundland A-G identifies potential fraud in travel nurse agency billings' (June 26): Better late than never, but why so late? Sixteen months after an admirably extensive and detailed Globe and Mail investigation ('Have nurses, will travel'), the Newfoundland and Labrador Auditor-General now reports findings that are, surprisingly, described as 'surprising.' Curiously absent in the long-overdue report is the typical ministry response. Audit best practices require management to acknowledge findings and commit to corrective actions with responsibilities, timelines and resources. A 2025 Ontario Auditor-General report on the safety of non-municipal drinking water contained 17 recommendations. Ministry of Health responses blandly agreed, but promises to 'evaluate,' 'consider' and 'explore options' proposed no timelines or accountabilities. This pattern of reluctance to confront problems until publicly exposed, then dodge responsibility, echoes federal disasters such as Phoenix and ArriveCan and serves as a cautionary reminder of the challenges facing incoming clerk of the Privy Council Michael Sabia. Chester Fedoruk Toronto Re 'The false world of mommy influencers' (Opinion, June 28): Oh, to be very young, photogenic and rich so you can offer breezy advice on achieving your (mostly) fantasy life! I'm all for new, fresh voices joining the conversation about shaping society, but more than equal weight must be given to years of hard-earned experience. To quote that famous influencer RuPaul, 'You better work.' Mike Karapita Toronto Re 'When 'justice' is a joke' (Opinion, June 28): I read with some interest your columnist's take on the sentencing of the young woman who was convicted of being an accessory to Karolina Huebner-Makurat's tragic murder. And by inference her support of Ontario Premier Doug Ford's criticism of 'left-leaning lenient judges.' Most people, I am sure, winced about the details behind Khalila Mohammed's offence. But your writer's view of what an appropriate sentence is falls back on tired notions, particularly that incarceration is the only form of 'real' deterrence. I am not privy to the evidence and submissions regarding Ms. Mohammed's background for the sentencing, but I venture to say it revealed she was sincerely remorseful and that her rehabilitation was well under way. And it would be hard to underestimate the crushing public opprobrium and personal humiliation that resulted from the nationally publicized details concerning her arrest and conviction. There is also the very real risk that sending someone to jail endangers their progress and commitment to social values – in your columnist's parlance, the 'lie down with dogs, get up with fleas' principle. I have no doubt that Justice Russell Silverstein would not shrink from imposing a substantial jail sentence if that had been appropriate for the offender in front of him. But in this case he didn't do what was popular, to your columnist or to the Premier of Ontario, for that matter. However, I have to think he did the right thing, not just for the individual involved but for the people of Ontario. It's now up to Ms. Mohammed to show whether he was right or wrong. Joe Wright Toronto Re 'What is behind Carney walking back the DST?' (Report on Business, July 1): Like Taylor C. Noakes, I am sorely disappointed in Mark Carney for cancelling the digital services tax. In fact, I'm kind of in a rage. All I can think of to do is to 'tax' those big American companies myself, by boycotting them. I'm cancelling my Amazon membership, forgoing Prime, using local taxi companies instead of Uber. I urge all Canadians to consider hitting back at those American transnationals that won't even pay a paltry 3 per cent in taxes to the Canadians who pay them billions. Carney may have caved, but the rest of us don't have to. Audrey Samson Halifax Prime Minister Mark Carney has shown regrettable weakness in cancelling the digital services tax – and he may be disappointed if he thinks that concession will be enough to get trade talks back on track. As Taylor C. Noakes argues, there is a perfectly good policy basis for taxing the enormous profits that American tech giants make in Canada. Now what will happen when President Donald Trump goes after our dairy and poultry supply management system, about which he has quite legitimate grounds for complaint, given its protectionist and market-distorting nature? Will that become the hill the Prime Minister chooses to die on? Peter Maitland Lindsay, Ont. Re 'Carney 'caved' on DST, according to U.S.' (July 1): It pains me to find myself in agreement with both the White House and Pierre Poilievre that the Carney Liberals 'caved' on the digital services tax. We've just watched the spectacle of tech oligarch Jeff Bezos essentially buying Venice for his multimillion-dollar wedding extravaganza, but we don't have the stomach to insist that he pay a 3-per-cent tax on the business he does in Canada? Those tax dollars are needed to finance all kinds of public infrastructure and services that support Amazon's success. Bezos and his tech bros need to pay their fair share. What happened to the promise of 'elbows up' – standing our ground and defending our values? Susan Watson Guelph, Ont. For those who say Canada caved to President Trump when the DST was cancelled, I remind them that we were not obliterated. Peter Woolstencroft Waterloo .................................................................................................................................. Letters to the Editor should be exclusive to The Globe and Mail. Include your name, address and daytime phone number. Keep letters to 150 words or fewer. Letters may be edited for length and clarity. To submit a letter by e-mail, click here: letters@
